Hydroxocobalamin G.L. Pharma

Hydroxocobalamin, the active ingredient in Hydroxocobalamin G.L. Pharma, is a vitamin B12 drug presented as an injectable solution for intramuscular use. It is used to treat vitamin B12 deficiency and to bind cyanide in cases of cyanide poisoning. GNH USA supplies Hydroxocobalamin G.L. Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, oncology centres, transplant centres and clinics worldwide.

Hydroxocobalamin acts on metabolic pathways that require cobalamin as a cofactor, addressing conditions linked to its deficiency or toxic exposure.

Vitamin B12 deficiency: restores normal cobalamin levels and supports red blood cell formation. Cyanide poisoning: binds cyanide ions to form cyanocobalamin, facilitating detoxification.

Hydroxocobalamin may cause adverse reactions, most of which are mild to moderate.

Common Side Effects: - Injection site pain or erythema - Headache - Nausea or mild gastrointestinal upset - Flushing or warmth sensation - Mild hypertension - Dizziness

Serious or Rare Side Effects: - Anaphylactic or severe allergic reaction - Severe hypertension or hypertensive crisis - Acute hemolysis in susceptible individuals - Thromboembolic events - Severe skin reactions (e.g., Stevens‑Johnson syndrome)

When using Hydroxocobalamin, consider the following safety measures. - Assess patient history: check for prior hypersensitivity to cobalamin preparations. - Monitor blood pressure: watch for sudden increases after injection. - Evaluate renal function: adjust use in severe renal impairment. - Observe for allergic reactions: be prepared to manage anaphylaxis. - Use caution in pregnancy and lactation: only if clearly needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Hydroxocobalamin can interact with other agents, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Metformin: may mask B12 deficiency, requiring monitoring. - Nitrous oxide anesthesia: can inactivate cobalamin, increasing deficiency risk.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may reduce absorption of oral B12, less relevant for IM but note overall B12 status. - Anticonvulsants (e.g., phenytoin, carbamazepine): may affect B12 metabolism. - Chemotherapeutic agents: monitor hematologic parameters when combined.